Zealand Pharma A/S (Zealand) (CPH:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Friday the return by Boehringer Ingelheim of an Amylin analog that was being developed for the treatment of obesity and Type 2 diabetes.
Reportedly, the Amylin analog programme was licensed to Boehringer Ingelheim in 2014 to conduct and finance all clinical development and commercialisation, with Zealand eligible to receive milestone payments and royalties on global sales.
As of 20 March 2020, this license agreement will no longer be active. The long-term partnership will continue with the license agreement to develop the GLP-1/glucagon analog BI 456906, which is planned to advance into phase 2 development.
Zealand added that it will communicate the potential of further development of the Amylin programme at a later stage, following a thorough evaluation.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes